Devlin MJ

No ORCID on file · 2 papers in corpus · active 2023-2025
2025
JAMA oncology ·doi:10.1001/jamaoncol.2024.6797

ImportanceAdvanced clear cell gynecological cancers (CCGCs) have a poor prognosis, with response rates to second-line chemotherapy less than 8%. Preliminary clinical activity with programmed cell death 1 protein (PD-1) inhibitors reported i…

2023
Therapeutic advances in medical oncology ·doi:10.1177/17588359221148024

The treatment of high-grade serous ovarian cancer and high-grade endometrioid ovarian cancer has seen significant improvements in recent years, with BRCA1/2 and homologous recombination status guiding a personalized approach which has resul…